PDT | Jotup

Cadence’s Anirudh Devgan to Present at J.P. Morgan Conference

Retrieved on:

Dienstag, Mai 14, 2024

Semiconductor, Hardware, Electronic Design Automation, Technology, Software, Cadence Design Systems, Devgan, Webcast, CDNS, Conference, PDT

Anirudh Devgan, president and chief executive officer, Cadence Design Systems, Inc. (Nasdaq: CDNS).

Key Points:

Anirudh Devgan, president and chief executive officer, Cadence Design Systems, Inc. (Nasdaq: CDNS).
Devgan will participate in a fireside chat at the 52nd Annual J.P. Morgan Global Technology Media and Communications Conference on Tuesday, May 21, 2024.
The talk will be available live by webcast at 8:30 a.m. PDT on Tuesday, May 21, 2024.
The presentation will be archived on the Cadence website and will be available for replay for 30 days.

CV Sciences, Inc. Reports First Quarter 2024 Financial Results

Retrieved on:

Dienstag, Mai 14, 2024

Sale, SAN, Global health, Acquisition, Environment, OTCQB, Hip, PDT, Video game

Our revenues increased sequentially to $4 million in the first quarter 2024 in a challenging environment.

Key Points:

Our revenues increased sequentially to $4 million in the first quarter 2024 in a challenging environment.
Our 46.3% gross margin in the first quarter 2024 is our best gross margin in the last 12 quarters," stated Joseph Dowling, Chief Executive Officer of CV Sciences.
Sales for first quarter 2024 were $4.0 million, a decrease of 4% from $4.1 million in the first quarter 2023.
The Company had negative adjusted EBITDA of $0.5 million for the first quarter 2024 compared to $0.2 million in the first quarter of 2023.

Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention

Retrieved on:

Samstag, Mai 11, 2024

Cellulite, Connective tissue, Biotechnology, Dercum's disease, San Diego Convention Center, Biotechnology Innovation Organization, PDT, BIO

NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.

Key Points:

NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.
The presentation will take place in Company Presentation Theater 2 at the San Diego Convention Center.
The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), stands as the world's premier industry event, convening over 20,000 esteemed biotechnology and pharmaceutical leaders from around 5,000 reputable companies.
Caliway anticipates this opportunity to share recent progress on its lead pipeline candidate, CBL-514, with the international biotechnology and pharmaceutical community.

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Retrieved on:

Mittwoch, April 10, 2024

Corporation, NEC, Phase, Cancer, Chemoradiotherapy, AI, Poster, PDT, Health care, Euronext Paris, Intelligence, Disease, Patient, Neoplasm, Head, AACR, Curie Institute (Paris), Vaccine

TG4050 is based on Transgene's myvac platform and powered by NEC's cutting-edge AI capabilities designed to optimize antigen selection.

Key Points:

TG4050 is based on Transgene's myvac platform and powered by NEC's cutting-edge AI capabilities designed to optimize antigen selection.
TG4050 is starting to show a potential benefit for head and neck cancer patients at high risk of relapse.
We look forward to starting the Phase II part of the trial in the adjuvant setting for head and neck cancer."
The poster can be viewed in-person during the poster presentation at the AACR 2024 meeting and accessed on Transgene's website.

Cadence’s Nimish Modi to Present at Needham Conference

Retrieved on:

Donnerstag, Mai 9, 2024

Software, Technology, Electronic Design Automation, Semiconductor, Cadence Design Systems, Narendra Modi, PDT, CDNS, Conference, Webcast

Nimish Modi, senior vice president and general manager, Strategy & New Ventures, Cadence Design Systems, Inc. (Nasdaq: CDNS).

Key Points:

Nimish Modi, senior vice president and general manager, Strategy & New Ventures, Cadence Design Systems, Inc. (Nasdaq: CDNS).
Modi will participate in a virtual fireside chat at the 19th Annual Needham Technology, Media, & Consumer Conference on Thursday, May 16, 2024.
The talk will be available live by webcast at 9:45 a.m. PDT on Thursday, May 16, 2024.
The presentation will be archived on the Cadence website and will be available for replay for 90 days.

Nevro to Present at BofA Securities 2024 Healthcare Conference

Retrieved on:

Donnerstag, Mai 9, 2024

Bank of America, BofA Securities, PDT, EDT, Chronic pain, Conference

REDWOOD CITY, Calif., May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.

Key Points:

REDWOOD CITY, Calif., May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.
The company's formal presentation will begin at 9:20 am PDT (12:20 am EDT).
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com .
The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

Solventum Reports First Quarter 2024 Financial Results and Capital Allocation Update

Retrieved on:

Donnerstag, Mai 9, 2024

Solventum now expects an unfavorable impact from foreign exchange of ~50bps on reported sales for the full year 2024.

Key Points:

Solventum now expects an unfavorable impact from foreign exchange of ~50bps on reported sales for the full year 2024.
3M supply agreement mark-up started on April 1, 2024, and Solventum anticipates impact to the income statement to begin largely in the second half of 2024.
Solventum's full-year 2024 guidance is based on Q1 2024 3M carve-out financial information and expected results for the remainder of the year as a stand-alone company, starting April 1, 2024.
The Q1 2024 financial statements and financial information, including reconciliations of non-GAAP financial measures and certain prior period reconciliations, are available on Solventum's website: https://investors.solventum.com .

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

Retrieved on:

Donnerstag, Mai 9, 2024

Webcast, PDT, Lexicon, Bank, Lexicon Pharmaceuticals, Conference

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024.

Key Points:

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024.
Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET).
A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.

LogicMark, Inc. to Present at Aegis Capital Corp. Virtual Conference on May 9, 2024

Retrieved on:

Mittwoch, Mai 8, 2024

CFO, PDT, EDT, Conference, PERS, LGMK

LOUISVILLE, Ky., May 08, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing care economy, today announced that Ms. Chia-Lin Simmons, CEO, and Mr. Mark Archer, CFO will speak at the virtual Aegis Capital Corp. Conference on Thursday, May 9th at 11:00 PDT / 2:00 pm EDT.

Key Points:

LOUISVILLE, Ky., May 08, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing care economy, today announced that Ms. Chia-Lin Simmons, CEO, and Mr. Mark Archer, CFO will speak at the virtual Aegis Capital Corp. Conference on Thursday, May 9th at 11:00 PDT / 2:00 pm EDT.
Please register here to attend the conference:

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

Retrieved on:

Mittwoch, Mai 8, 2024

“These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.

Key Points:

“These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.
CX-904 Phase 1a dose escalation and optimization continue, with future enrollment focused on determining a recommended Phase 2 dose, or doses.
The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
These additional data will inform discussions with CytomX partner, Amgen, towards initiation of Phase 1b expansion cohorts in specific EGFR positive tumor types.